CAMBRIDGE, United Kingdom: AstraZeneca’s blood most cancers remedy, Calquence, failed to enhance survival charges and forestall lung failure in sufferers hospitalised with signs of COVID-19, the drugmaker stated on Thursday (Nov 12), citing outcomes from mid-stage trials.
The corporate known as the result “disappointing”. It stated its different efforts to fight the pandemic – a attainable vaccine developed with Oxford College, and an experimental antibody-based COVID-19 remedy – weren’t affected.
READ: Moderna might start analysing COVID-19 vaccine information inside days, says Fauci
AstraZeneca is amongst main contenders within the race for a working vaccine for the novel coronavirus. Competitor Pfizer this week revealed efficacy information that have been seen as a serious milestone on the best way to a worldwide immunisation marketing campaign subsequent yr.
Calquence, chemically known as acalabrutinib, belongs to a category of medicine known as Bruton’s tyrosine kinase (BTK) inhibitors which may suppress autoimmune illnesses – situations the place the physique’s immune system mistakenly assaults the physique itself.
COVID-19 sufferers with extreme signs together with pneumonia are believed to undergo from an overreaction of the immune system often known as cytokine storm.
READ: Commentary: Pfizer reaches COVID-19 vaccine breakthrough – a step nearer to pandemic’s finish
READ: Commentary: Why dashing a COVID-19 vaccine might spell catastrophe
AstraZeneca had aimed to check whether or not Calquence, which suppresses sure components of the immune system, can include this immune response.
Outcomes from the trials won’t affect authorised indications or pending approvals for Calquence in sufferers with blood cancers, the British firm stated.
The drug, which is already used to deal with sure kinds of cancers of the blood, is an authorised remedy of grownup sufferers with persistent lymphocytic leukaemia in america and several other different nations.
BOOKMARK THIS: Our complete protection of the coronavirus outbreak and its developments
Obtain our app or subscribe to our Telegram channel for the most recent updates on the coronavirus outbreak: https://cna.asia/telegram